Lilani P Perera1, Mark Radigan2, Corinne Guilday3, Indrani Banerjee4, Daniel Eastwood5, Reji Babygirija6, Benson T Massey2. 1. Inflammatory Bowel Disease Center, Aurora Healthcare, 975 Port Washington Rd, Grafton, WI, 53024, USA. Lilani.Perera@aurora.org. 2. Medical College of Wisconsin, Milwaukee, WI, USA. 3. Washington University, St. Louis, MO, USA. 4. Michigan State University, East Lansing, MI, USA. 5. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. 6. Aurora Research Institute, Milwaukee, WI, USA.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD; Crohn's disease, CD and Ulcerative colitis, UC) and irritable bowel syndrome (IBS) have overlapping symptoms. Few prevalence studies of IBS in quiescent IBD have used colonoscopy with histology to confirm inactive disease. The aims were (1) to determine the percentage of IBD patients in deep remission whose persistent IBS-like symptoms (IBD/IBS+) would cause them to be classified as having active disease, based on the calculation of Harvey Bradshaw Index (HBI) or UC disease activity index (UCDAI); (2) to identify demographic and disease characteristics that are associated with IBD/IBS+. METHODS: This was a prospective study at a single tertiary care IBD center. 96/112 patients with colonoscopy and histology confirmed quiescent disease consented and completed Rome III criteria for IBS Survey, and the hospital anxiety and depression scale (HADS). Other demographic and disease specific data were collected. RESULTS: 36% (28/77) and 37% (7/19) of CD and UC patients, respectively, met diagnostic criteria for IBS. Significantly higher HBI/UCDAI scores (p = 0.005) and low short inflammatory bowel disease questionnaire (SIBDQ) scores (p ≤ 0.0001) were seen in IBD/IBS+ patients. 29% of patients in deep remission were mis-categorized by HBI/UCDAI as having active disease when they fulfilled Rome III criteria for IBS. Psychiatric diagnosis (OR 3.53 95% CI 1.2-10.2) and earlier onset of IBD (OR 1.056 95% CI 1.015-1.096) were associated with IBD/IBS+. Patients fulfilling IBS criteria had higher hospital anxiety and depression scale (HADS). CONCLUSION: IBD/IBS+ affect scoring of IBD disease activity scales and become less useful in guiding treatment plans.
BACKGROUND: Inflammatory bowel disease (IBD; Crohn's disease, CD and Ulcerative colitis, UC) and irritable bowel syndrome (IBS) have overlapping symptoms. Few prevalence studies of IBS in quiescent IBD have used colonoscopy with histology to confirm inactive disease. The aims were (1) to determine the percentage of IBD patients in deep remission whose persistent IBS-like symptoms (IBD/IBS+) would cause them to be classified as having active disease, based on the calculation of Harvey Bradshaw Index (HBI) or UC disease activity index (UCDAI); (2) to identify demographic and disease characteristics that are associated with IBD/IBS+. METHODS: This was a prospective study at a single tertiary care IBD center. 96/112 patients with colonoscopy and histology confirmed quiescent disease consented and completed Rome III criteria for IBS Survey, and the hospital anxiety and depression scale (HADS). Other demographic and disease specific data were collected. RESULTS: 36% (28/77) and 37% (7/19) of CD and UC patients, respectively, met diagnostic criteria for IBS. Significantly higher HBI/UCDAI scores (p = 0.005) and low short inflammatory bowel disease questionnaire (SIBDQ) scores (p ≤ 0.0001) were seen in IBD/IBS+ patients. 29% of patients in deep remission were mis-categorized by HBI/UCDAI as having active disease when they fulfilled Rome III criteria for IBS. Psychiatric diagnosis (OR 3.53 95% CI 1.2-10.2) and earlier onset of IBD (OR 1.056 95% CI 1.015-1.096) were associated with IBD/IBS+. Patients fulfilling IBS criteria had higher hospital anxiety and depression scale (HADS). CONCLUSION: IBD/IBS+ affect scoring of IBD disease activity scales and become less useful in guiding treatment plans.
Authors: Smita L S Halder; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; L Joseph Melton; Nicholas J Talley Journal: Gastroenterology Date: 2007-06-20 Impact factor: 22.682
Authors: Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson Journal: Am J Gastroenterol Date: 2002-02 Impact factor: 10.864
Authors: George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Awni Abu Sneineh; Sara Haj Ali; Ahmad Al-Masri; Amr Diab; Farah Aldweik; Mohammad Darweesh; Mohammad Qaisi; Osama Alshakhatreh; Tarek Tamimi; Yaser Rayyan; Radwan Banimustafa; Ibrahim Sablaban Journal: Sci Rep Date: 2022-05-10 Impact factor: 4.996
Authors: Maria G Grammatikopoulou; Dimitrios G Goulis; Konstantinos Gkiouras; Meletios P Nigdelis; Stefanos T Papageorgiou; Theodora Papamitsou; Alastair Forbes; Dimitrios P Bogdanos Journal: Nutrients Date: 2020-11-27 Impact factor: 5.717